Atossa Therapeutics, Inc. (ATOS)
2.65
-0.03
(-1.12%)
USD |
NASDAQ |
Aug 26, 16:00
2.67
+0.02
(+0.75%)
After-Hours: 20:00
Atossa Therapeutics EPS Diluted (Quarterly) : -0.9531 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.9531 |
| March 31, 2026 | -1.112 |
| December 31, 2025 | -1.270 |
| September 30, 2025 | -1.009 |
| June 30, 2025 | -0.9782 |
| March 31, 2025 | -0.052 |
| December 31, 2024 | -0.752 |
| September 30, 2024 | -0.0575 |
| June 30, 2024 | -0.0481 |
| March 31, 2024 | -0.0469 |
| December 31, 2023 | -0.0619 |
| September 30, 2023 | -0.0495 |
| June 30, 2023 | -0.0776 |
| March 31, 2023 | -0.0496 |
| December 31, 2022 | -0.0592 |
| September 30, 2022 | -0.0633 |
| June 30, 2022 | -0.0527 |
| March 31, 2022 | -0.0378 |
| December 31, 2021 | -0.0382 |
| September 30, 2021 | -0.0411 |
| June 30, 2021 | -0.0579 |
| March 31, 2021 | -0.0382 |
| December 31, 2020 | -0.8853 |
| September 30, 2020 | -0.3435 |
| June 30, 2020 | -0.4252 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.3228 |
| December 31, 2019 | -0.2867 |
| September 30, 2019 | -0.3599 |
| June 30, 2019 | -0.7958 |
| March 31, 2019 | -0.6204 |
| December 31, 2018 | -0.3554 |
| September 30, 2018 | -0.6385 |
| June 30, 2018 | -5.082 |
| March 31, 2018 | -0.7068 |
| December 31, 2017 | -0.7516 |
| September 30, 2017 | -2.16 |
| June 30, 2017 | -7.68 |
| March 31, 2017 | -5.40 |
| December 31, 2016 | -7.997 |
| September 30, 2016 | 0.84 |
| June 30, 2016 | -7.20 |
| March 31, 2016 | -12.60 |
| September 30, 2015 | -6318.00 |
| June 30, 2015 | -297.00 |
| March 31, 2015 | -23.40 |
| December 31, 2014 | -42.60 |
| September 30, 2014 | -23.40 |
| June 30, 2014 | -23.49 |
| March 31, 2014 | -18.00 |
| December 31, 2013 | -27.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Immix Biopharma, Inc. | -0.1812 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.491M |
| Total Expenses (Quarterly) | 8.491M |
| Enterprise Value | 0.2411M |
| Earnings Yield | -164.0% |
| Normalized Earnings Yield | -163.95 |